Kexon Pharmaceuticals announced that in the first half of 2026, it achieved operating income of 607 million yuan, net profit attributable to shareholders of listed companies of 134 million yuan, an increase of 66.71% over the previous year; R&D investment was 128 million yuan, an increase of 33.08% over the previous year. In the first half of the year, 9 high-value products were introduced, and 32 new overseas registrations were accepted and 29 new approvals were added. The distribution of equity in 2025 was completed, with a total distribution of RMB 2.50 for every 10 shares, totaling RMB 494.656 million; the share repurchase was completed in 2025, with a total repurchase of 1,514,400 shares, accounting for 0.75% of the total share capital, and a payment amount of RMB 55.646 million.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.